stockrowIM Cannabis Corp.
IMCC Healthcare Drug Manufacturers Specialty & Generic
IM Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 0.66% from fiscal 2024.
- Revenue
- −40.3%
- EPS
- −385.7%
- Free cash flow
- −266.8%
- Total debt
- −64.7%
Quarter to June 2026, against a year earlier
Follow IMCC
Alert me
IM Cannabis Corp. (IMCC) EV/Sales
As of 5 November 2026, IM Cannabis Corp. (IMCC) trades at a EV/Sales of 0.0×. Over the past ten years it has ranged from 0.0× (November 2026) to 32.7× (March 2021) — the current reading is the lowest in ten years. That is below the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.1× | (28.99%) |
| FY2024 | 0.2× | (46.26%) |
| FY2023 | 0.3× | (5.20%) |
| FY2022 | 0.3× | (93.03%) |
| FY2021 | 4.7× | (81.06%) |
| FY2020 | 24.8× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.0× | (41.94%) |
| Mar 2026 | 0.1× | (44.97%) |
| Dec 2025 | 0.1× | (50.00%) |
| Sep 2025 | 0.2× | 0.77% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SXTC China SXT Pharmaceuticals, Inc. compare | −5.9× |
| SBFM Sunshine Biopharma, Inc. compare | −0.3× |
| IMCC IM Cannabis Corp. | 0.0× |
| AKAN Akanda Corp. compare | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| PTPI Petros Pharmaceuticals, Inc. compare | 0.6× |
| RDHL Redhill Biopharma Ltd. compare | 6.4× |
| BTAIQ BioXcel Therapeutics, Inc. compare | 228× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)